elucidated that an ECM-related gene, TGF-beta-induced (TGFBI), expression was significantly increased in drug-sensitive ovarian cancer patients compared with drug-resistant patients, and in vitro experiments showed that TGFBI-associated integrin signaling pathway could be related to paclitaxel sensitivity of ovarian cancer and breast cancer cell lines (23). This evidence concerns the gene TGFBI and breast carcinoma.